How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States

Journal of Urology

Volumn 196, Issue 3, 2016, Pages 721-726

  Loeb, Stacy ^a,b   Walter, Dawn ^a   Curnyn, Caitlin ^a   Gold, Heather T ^a   Lepor, Herbert ^a   Makarov, Danil V ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aged; prostatic neoplasms; SEER program; standard of care; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGE; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; FOLLOW UP; HUMAN; HUMAN TISSUE; INCOME; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; UNITED STATES; BIOPSY; BLOOD; CANCER REGISTRY; CLINICAL TRIAL; MORBIDITY; MULTICENTER STUDY; PATHOLOGY; PATIENT COMPLIANCE; PROSTATE; PROSTATE TUMOR; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MORBIDITY; PATIENT COMPLIANCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 84992317658     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.02.2963     Document Type: Article

References (23)

1. National Comprehensive Cancer Network 2016 Clinical Practice Guidelines: Prostate Cancer Treatment. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed January 25, 2016.
2. Womble, P.R., Montie, J.E., Ye, Z., et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol, 67, 2015, 44.
3. Loeb, S., Berglund, A., Stattin, P., Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol, 190, 2013, 1742.
4. Weerakoon, M., Papa, N., Lawrentschuk, N., et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int, 115(suppl.), 2015, 50.
5. Cooperberg, M.R., Carroll, P.R., Trends in management for patients with localized prostate cancer, 1990-2013. JAMA, 314, 2015, 80.
6. Carter, H.B., Walsh, P.C., Landis, P., et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol, 167, 2002, 1231.
7. Klotz, L., Vesprini, D., Sethukavalan, P., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol, 33, 2015, 272.
8. Bul, M., Zhu, X., Valdagni, R., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol, 63, 2013, 597.
9. National Cancer Institute, Surveillance, Epidemiology, and End Results Program: Overview of the SEER Program. Available at http://seer.cancer.gov/about/overview.html. Accessed February 8, 2016.
10. Filson, C.P., Schroeck, F.R., Ye, Z., et al. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. J Urol, 192, 2014, 75.
11. National Comprehensive Cancer Network 2016 Clinical Practice Guidelines: Prostate Cancer. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
12. Klabunde, C.N., Legler, J.M., Warren, J.L., et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol, 17, 2007, 584.
13. Furlow, B., US National Cancer Institute investigates PSA coding errors. Lancet Oncol, 16, 2015, 614.
14. Tosoian, J.J., Trock, B.J., Landis, P., et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol, 29, 2011, 2185.
15. Tosoian, J.J., Mamawala, M., Epstein, J.I., et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol, 33, 2015, 3379.
16. Anai, S., Nakamura, K., Chang, M.N., et al. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer. J Health Care Poor Underserved, 19, 2008, 164.
17. Lee, E.K., Baack, J., Penn, H., et al. Active surveillance for prostate cancer in a veteran population. Can J Urol, 17, 2010, 5429.
18. Ritchey, J., Gay, E.G., Spencer, B.A., et al. Assessment of the quality of medical care among patients with early stage prostate cancer undergoing expectant management in the United States. J Urol, 188, 2012, 769.
19. Chamie, K., Williams, S.B., Hershman, D.L., et al. Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer, 121, 2015, 4150.
20. International Agency for Research on Cancer, World Health Organization: GLOBOCAN 2012 Prostate Cancer Fact Sheet. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed September 20, 2015.
21. Eggener, S., How active should active surveillance be?. BJU Int, 115, 2015, 176.
22. Bratt, O., Carlsson, S., Holmberg, E., et al. The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol, 47, 2013, 347.
23. Fascelli, M., George, A.K., Frye, T., et al. The role of MRI in active surveillance for prostate cancer. Curr Urol Rep, 16, 2015, 42.